South Korea · Delayed Price · Currency is KRW Wonbiogen Statistics
Total Valuation
Wonbiogen has a market cap or net worth of KRW 47.74 billion. The enterprise value is 33.21 billion.
| Market Cap | 47.74B |
| Enterprise Value | 33.21B |
Important Dates
The next estimated earnings date is Friday, April 3, 2026.
| Earnings Date | Apr 3, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Wonbiogen has 7.09 million shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 7.09M |
| Shares Outstanding | 7.09M |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | 32.43% |
| Owned by Institutions (%) | n/a |
| Float | 4.79M |
Valuation Ratios
The trailing PE ratio is 7.21.
| PE Ratio | 7.21 |
| Forward PE | n/a |
| PS Ratio | 1.35 |
| PB Ratio | 1.12 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | 7.33 |
| P/OCF Ratio | 5.63 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.48, with an EV/FCF ratio of 5.10.
| EV / Earnings | 5.02 |
| EV / Sales | 0.94 |
| EV / EBITDA | 3.48 |
| EV / EBIT | 4.13 |
| EV / FCF | 5.10 |
Financial Position
The company has a current ratio of 6.00, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.00 |
| Quick Ratio | 4.63 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.10 |
| Debt / FCF | 0.14 |
| Interest Coverage | 203.49 |
Financial Efficiency
Return on equity (ROE) is 16.17% and return on invested capital (ROIC) is 24.18%.
| Return on Equity (ROE) | 16.17% |
| Return on Assets (ROA) | 11.52% |
| Return on Invested Capital (ROIC) | 24.18% |
| Return on Capital Employed (ROCE) | 19.00% |
| Weighted Average Cost of Capital (WACC) | 7.89% |
| Revenue Per Employee | 457.72M |
| Profits Per Employee | 85.91M |
| Employee Count | 77 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 3.06 |
Taxes
In the past 12 months, Wonbiogen has paid 1.32 billion in taxes.
| Income Tax | 1.32B |
| Effective Tax Rate | 16.99% |
Stock Price Statistics
The stock price has increased by +25.86% in the last 52 weeks. The beta is 0.68, so Wonbiogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | +25.86% |
| 50-Day Moving Average | 7,243.00 |
| 200-Day Moving Average | 6,058.68 |
| Relative Strength Index (RSI) | 38.41 |
| Average Volume (20 Days) | 26,157 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Wonbiogen had revenue of KRW 35.24 billion and earned 6.62 billion in profits. Earnings per share was 933.00.
| Revenue | 35.24B |
| Gross Profit | 17.77B |
| Operating Income | 8.19B |
| Pretax Income | 7.78B |
| Net Income | 6.62B |
| EBITDA | 9.70B |
| EBIT | 8.19B |
| Earnings Per Share (EPS) | 933.00 |
Balance Sheet
The company has 15.36 billion in cash and 930.65 million in debt, with a net cash position of 14.43 billion or 2,034.26 per share.
| Cash & Cash Equivalents | 15.36B |
| Total Debt | 930.65M |
| Net Cash | 14.43B |
| Net Cash Per Share | 2,034.26 |
| Equity (Book Value) | 42.62B |
| Book Value Per Share | 6,035.34 |
| Working Capital | 22.56B |
Cash Flow
In the last 12 months, operating cash flow was 8.48 billion and capital expenditures -1.97 billion, giving a free cash flow of 6.51 billion.
| Operating Cash Flow | 8.48B |
| Capital Expenditures | -1.97B |
| Depreciation & Amortization | 1.51B |
| Net Borrowing | -444.47M |
| Free Cash Flow | 6.51B |
| FCF Per Share | 917.99 |
Margins
Gross margin is 50.42%, with operating and profit margins of 23.24% and 18.77%.
| Gross Margin | 50.42% |
| Operating Margin | 23.24% |
| Pretax Margin | 22.08% |
| Profit Margin | 18.77% |
| EBITDA Margin | 27.52% |
| EBIT Margin | 23.24% |
| FCF Margin | 18.48% |
Dividends & Yields
This stock pays an annual dividend of 140.00, which amounts to a dividend yield of 2.11%.
| Dividend Per Share | 140.00 |
| Dividend Yield | 2.11% |
| Dividend Growth (YoY) | 40.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 10.72% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 2.07% |
| Earnings Yield | 13.86% |
| FCF Yield | 13.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 7, 2025. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Wonbiogen has an Altman Z-Score of 7.61 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.61 |
| Piotroski F-Score | 6 |